Quick Answer
Pea Protein Satiety Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: In particular, whey protein has demonstrated strong potential for postprandial glucose management, and more recent findings highlighted evidence for increased efficacy of whey protein when consumed before, rather than with a carbohydrate-rich meal.
Key Takeaways
- 01In particular, whey protein has demonstrated strong potential for postprandial glucose management, and more recent findings highlighted evidence for increased efficacy of whey protein when consumed before, rather than with a carbohydrate-rich meal. [Elbira A (2026)]
- 02Given the strong interest yet limited evidence on plant-based protein, the present study compared the potential of pea protein consumed prior to carbohydrates, on postprandial glucose as well as satiety and blood pressure (BP). [Elbira A (2026)]
- 03Results Both PP and PrePP significantly reduced postprandial glucose excursion (0.46 vs. [Elbira A (2026)]
- 04Purpose Protein intake has shown benefits to mitigate postprandial hyperglycaemic excursions. [Elbira A (2026)]
The current Migaku evidence database contains 2 reusable source documents for Pea Protein Satiety Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- In particular, whey protein has demonstrated strong potential for postprandial glucose management, and more recent findings highlighted evidence for increased efficacy of whey protein when consumed before, rather than with a carbohydrate-rich meal. [Elbira A (2026); evidence level 2]
- Given the strong interest yet limited evidence on plant-based protein, the present study compared the potential of pea protein consumed prior to carbohydrates, on postprandial glucose as well as satiety and blood pressure (BP). [Elbira A (2026); evidence level 2]
- Results Both PP and PrePP significantly reduced postprandial glucose excursion (0.46 vs. [Elbira A (2026); evidence level 2]
- Purpose Protein intake has shown benefits to mitigate postprandial hyperglycaemic excursions. [Elbira A (2026); evidence level 2]
- A novel fasting mimetic (Mimio) creates fasting-like benefits to hunger control, oxidative stress, and cardiometabolic health in humans. [Grant AD (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources